Abbott’s Q2 revenue tops expectations but shares fall

Published 17/07/2025, 12:44
© Reuters

Investing.com -- Abbott Laboratories reported second-quarter earnings that slightly exceeded analyst expectations, but shares fell 2.5% following the results.

The healthcare giant posted adjusted earnings per share of $1.26 for the second quarter, edging past the analyst consensus of $1.25. Revenue came in at $11.42 billion, significantly above the $11.07 billion analysts had expected, representing a 7.4% increase on a reported basis and 6.9% on an organic basis. When excluding COVID-19 testing-related sales, organic growth was 7.5%.

The company’s full-year 2025 EPS guidance came in at $5.10 to $5.20 compared to the analyst consensus of $5.16.

Medical (TASE:BLWV) Devices led growth with a 13.4% revenue increase, driven by strong performance in Diabetes Care where sales of continuous glucose monitors, including the FreeStyle Libre system, grew 21.4%. The Established Pharmaceuticals division saw 6.9% growth, while Nutrition sales increased 2.9%.

"Halfway through the year, we delivered high single-digit organic sales growth, double-digit EPS growth, significantly expanded our margin profiles, and continued to advance key programs through our new product pipeline," said Robert B. Ford, chairman and chief executive officer. "We see this momentum carrying into 2026."

The company reported improved profitability with adjusted gross margin of 57.0% of sales, reflecting a 100 basis point increase, and adjusted operating margin of 22.9%, also up 100 basis points.

For the full year 2025, Abbott projects organic sales growth of 7.5% to 8.0% excluding COVID-19 testing-related sales, or 6.0% to 7.0% when including these sales. The company also expects adjusted operating margin to be approximately 23.5% of sales.

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
© 2007-2025 - Fusion Media Limited. All Rights Reserved.